<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02061761</url>
  </required_header>
  <id_info>
    <org_study_id>CA224-022</org_study_id>
    <nct_id>NCT02061761</nct_id>
  </id_info>
  <brief_title>A Study to Evaluate the Safety, Tolerability, and Efficacy of Relatlimab in Relapsed or Refractory B-Cell Malignancies</brief_title>
  <official_title>A Phase 1/2a Dose Escalation and Cohort Expansion Study of the Safety, Tolerability, and Efficacy of Anti-LAG-3 Monoclonal Antibody (Relatlimab, BMS-986016) Administered Alone and in Combination With Anti-PD-1 Monoclonal Antibody (Nivolumab, BMS-936558) in Relapsed or Refractory B-Cell Malignancies</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bristol-Myers Squibb</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bristol-Myers Squibb</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of this study is to characterize the safety, tolerability,&#xD;
      dose-limiting toxicities (DLTs), and maximum tolerated dose (MTD) of relatlimab administered&#xD;
      alone or in combination with nivolumab to subjects with relapsed or refractory B-cell&#xD;
      malignancies. Co-primary objective is to investigate the preliminary efficacy of relatlimab&#xD;
      in combination with nivolumab in subjects with relapsed or refractory Hodgkin lymphoma (HL),&#xD;
      and relapsed or refractory Diffused Large B Cell lymphoma (DLBCL)&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">March 13, 2014</start_date>
  <completion_date type="Anticipated">June 4, 2022</completion_date>
  <primary_completion_date type="Anticipated">February 19, 2022</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of Adverse Events (AEs)</measure>
    <time_frame>Approximately 28 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of AEs leading to discontinuation</measure>
    <time_frame>Approximately 28 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of Serious Adverse Events (SAEs)</measure>
    <time_frame>Approximately 28 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of Deaths</measure>
    <time_frame>Approximately 28 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of clinically significant changes in clinical laboratory values: Hematology tests</measure>
    <time_frame>Approximately 28 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of clinically significant changes in clinical laboratory values: Chemistry tests</measure>
    <time_frame>Approximately 28 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of clinically significant changes in clinical laboratory values: Serology tests</measure>
    <time_frame>Approximately 28 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of clinically significant changes in clinical laboratory values: Endocrine panel</measure>
    <time_frame>Approximately 28 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of clinically significant changes in clinical laboratory values: Urinalysis</measure>
    <time_frame>Approximately 28 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of clinically significant changes in clinical laboratory values: Cardiac Troponin</measure>
    <time_frame>Approximately 28 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Objective response rate (ORR) in Part D</measure>
    <time_frame>Approximately 4 years</time_frame>
    <description>Efficacy measured by proportion of treated subjects with a best overall response of complete response/complete remission (CR) or partial response/partial remission (PR)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Duration of Response (DOR) in Part D</measure>
    <time_frame>Approximately 4 years</time_frame>
    <description>Efficacy measured by the duration of response for all treated subjects with a best overall response of CR or PR</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Maximum observed serum concentration (Cmax) of BMS-986016 administered alone and in combination with Nivolumab</measure>
    <time_frame>Approximately 28 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time of maximum observed serum concentration (Tmax) of BMS-986016 administered both alone and in combination with Nivolumab</measure>
    <time_frame>Approximately 28 Months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Trough observed serum concentration (Ctrough) of BMS-986016 administered both alone and in combination with Nivolumab</measure>
    <time_frame>Approximately 28 Months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Concentration at the end of a dosing interval (Ctau) of BMS-986016 administered both alone and in combination with Nivolumab</measure>
    <time_frame>Approximately 28 Months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Average concentration over a dosing interval [AUC(TAU)/tau] (Css,avg) of BMS-986016 administered both alone and in combination with Nivolumab</measure>
    <time_frame>Approximately 28 Months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the concentration-time curve in one dosing interval (AUC(TAU)) of BMS-986016 administered both alone and in combination with Nivolumab</measure>
    <time_frame>Approximately 28 Months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total body clearance (CLT) of BMS-986016 administered both alone alone and in combination with Nivolumab</measure>
    <time_frame>Approximately 28 Months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effective elimination half-life that explains the degree of AUC administered alone accumulation observed (T-HALFeff AUC) of BMS-986016 administered both alone and in combination with Nivolumab</measure>
    <time_frame>Approximately 28 Months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effective elimination half-life that explains the degree of Cmax administered alone accumulation observed (T-HALFeff Cmax) of BMS-986016 administered both alone and in combination with Nivolumab</measure>
    <time_frame>Approximately 28 Months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Accumulation index; ration of AUC(TAU) at steady state to AUC(TAU) after the first dose (AI_AUC) of BMS-986016 administered both alone and in combination with Nivolumab</measure>
    <time_frame>Approximately 28 Months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cmax accumulation index; ratio of Cmax at steady state to Cmax after the first dose (AI_Cmax) of BMS-986016 administered both alone and in combination with Nivolumab</measure>
    <time_frame>Approximately 28 Months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ctau accumulation index; ratio of Ctau at steady state to Ctau after the first dose (AI_Ctau) of BMS-986016 administered both alone and in combination with Nivolumab</measure>
    <time_frame>Approximately 28 Months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Degree of fluctuation or fluctuation index ([Cmax - Ctau]/Css,avg) (DF) of BMS-986016 administered both alone and in combination with Nivolumab</measure>
    <time_frame>Approximately 28 Months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of ADA to nivolumab and BMS-986016</measure>
    <time_frame>Approximately 28 Months</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">107</enrollment>
  <condition>Hematologic Neoplasms</condition>
  <arm_group>
    <arm_group_label>Part A - relatlimab (Dose escalation)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Part C - relatlimab + nivolumab (Dose escalation)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Part B - relatlimab (Cohort expansion)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Part D - relatlimab + nivolumab (Cohort expansion)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>BMS-986016</intervention_name>
    <description>Specified Dose on Specified Days</description>
    <arm_group_label>Part A - relatlimab (Dose escalation)</arm_group_label>
    <arm_group_label>Part B - relatlimab (Cohort expansion)</arm_group_label>
    <arm_group_label>Part C - relatlimab + nivolumab (Dose escalation)</arm_group_label>
    <arm_group_label>Part D - relatlimab + nivolumab (Cohort expansion)</arm_group_label>
    <other_name>Anti-LAG-3 (Anti-Lymphocyte Activation Gene-3), relatlimab</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>BMS-936558</intervention_name>
    <description>Specified Dose on Specified Days</description>
    <arm_group_label>Part C - relatlimab + nivolumab (Dose escalation)</arm_group_label>
    <arm_group_label>Part D - relatlimab + nivolumab (Cohort expansion)</arm_group_label>
    <other_name>Anti-PD-1 (Anti-Programmed-Death-1), MDX-1106, nivolumab</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        For more information regarding BMS clinical trial participation, please visit&#xD;
        www.BMSStudyConnect.com&#xD;
&#xD;
        Inclusion Criteria:&#xD;
&#xD;
          -  Must have histologic or cytologic confirmation of chronic lymphocytic leukemia,&#xD;
             Hodgkin lymphoma, Non-Hodgkin lymphoma, or Multiple Myeloma and have relapsed&#xD;
             following prior treatment or been refractory to prior treatment&#xD;
&#xD;
          -  Must have progressed or been refractory to, at least one prior standard therapy,&#xD;
             including radiation, immunomodulatory agents (eg, lenalidomide), immunotherapy,&#xD;
             cytotoxic chemotherapy, and select antibody (anti-CD20, alemtuzumab, or anti-CD30)&#xD;
             therapy.&#xD;
&#xD;
          -  Must be more than 100 days post autologous transplant&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Known or suspected central nervous system (CNS) metastases or with the CNS as the only&#xD;
             site of active disease (controlled CNS metastases are allowed)&#xD;
&#xD;
          -  Known or suspected autoimmune disease&#xD;
&#xD;
          -  History of allergy to anti-PD-1 or anti-PD-L1 antibody therapy or to other monoclonal&#xD;
             antibodies or related compounds or to any of their components&#xD;
&#xD;
        Other protocol-defined inclusion/exclusion criteria apply&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bristol-Myers Squibb</last_name>
    <role>Study Director</role>
    <affiliation>Bristol-Myers Squibb</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>The Sidney Kimmel Comprehensive Cancer Center</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21287</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dana Farber Cancer Institute</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Barbara Ann Karmanos Cancer Institute</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Washington University School Of Medicine</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Weill Cornell Medical College</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10021</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oregon Health &amp; Science University</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97239</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MD Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Washington</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>BC Cancer Agency - Vancouver Centre</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <zip>V5Z 4E6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Health Network - Princess Margaret Cancer Centre</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 2M9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://www.bms.com/researchers-and-partners/clinical-trials-and-research.html</url>
    <description>BMS Clinical Trial Information</description>
  </link>
  <link>
    <url>https://www.bmsstudyconnect.com/s/US/English/USenHome</url>
    <description>BMS Clinical Trial Patient Recruiting</description>
  </link>
  <link>
    <url>https://www.fda.gov/Safety/MedWatch/SafetyInformation/default.htm</url>
    <description>FDA Safety Alerts and Recalls</description>
  </link>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>February 12, 2014</study_first_submitted>
  <study_first_submitted_qc>February 12, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 13, 2014</study_first_posted>
  <last_update_submitted>September 26, 2021</last_update_submitted>
  <last_update_submitted_qc>September 26, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 1, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Hodgkin lymphoma</keyword>
  <keyword>non-Hodgkin lymphoma</keyword>
  <keyword>diffused large B-cell lymphoma</keyword>
  <keyword>indolent lymphoma</keyword>
  <keyword>chronic lymphocytic leukemia</keyword>
  <keyword>relapsed</keyword>
  <keyword>refractory</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hematologic Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nivolumab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

